Ayoxxa and SERI collaborate on protein multiplexing technology platform for ophthalmology

Ayoxxa has signed an agreement with the Singapore Eye Research Institute (SERI) to work together on validating the company's multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools.

Under the agreement, the companies will potentially use this technology as new diagnostic application in the treatment of age-related macular degeneration (AMD) (Ayoxxa News Release).